Syros Pharmaceuticals Inc [SYRS] stock is trading at $0.29, up 12.77%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The SYRS shares have gain 13.07% over the last week, with a monthly amount drifted -85.84%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Syros Pharmaceuticals Inc [NASDAQ: SYRS] stock has seen the most recent analyst activity on November 04, 2020, when H.C. Wainwright upgraded its rating to a Buy and also boosted its price target to $15 from $11. Previously, Alliance Global Partners started tracking the stock with Buy rating on September 22, 2020, and set its price target to $18. On January 17, 2020, downgrade downgraded it’s rating to Neutral. ROTH Capital upgraded its rating to Buy for this stock on November 05, 2018. In a note dated March 13, 2018, Wedbush reiterated an Outperform rating on this stock and boosted its target price from $11 to $13.
Syros Pharmaceuticals Inc [SYRS] stock has fluctuated between $0.18 and $8.17 over the past year. Currently, Wall Street analysts expect the stock to reach $16.67 within the next 12 months. Syros Pharmaceuticals Inc [NASDAQ: SYRS] shares were valued at $0.29 at the most recent close of the market. An investor can expect a potential return of 5648.28% based on the average SYRS price forecast.
Analyzing the SYRS fundamentals
Syros Pharmaceuticals Inc [NASDAQ:SYRS] reported sales of 0.39M for the trailing twelve months, which represents a drop of -100.00%. Gross Profit Margin for this corporation currently stands at -2.29% with Operating Profit Margin at -288.92%, Pretax Profit Margin comes in at -253.41%, and Net Profit Margin reading is -253.41%. To continue investigating profitability, this company’s Return on Assets is posted at -1.15, Equity is -27.47 and Total Capital is -1.97. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of-3.93.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 0.2678 points at the first support level, and at 0.2423 for the second support level. However, for the 1st resistance point, the stock is sitting at 0.3085, and for the 2nd resistance point, it is at 0.3237.
Ratios To Look Out For
For context, Syros Pharmaceuticals Inc’s Current Ratio is 2.25. As well, the Quick Ratio is 2.25, while the Cash Ratio is 2.05. Considering the valuation of this stock, the price to sales ratio is 22.76.
Transactions by insiders
Recent insider trading involved Stephens Kristin, Chief Development Officer, that happened on Nov 18 ’24 when 36133.0 shares were sold. Chief Medical Officer, Roth David completed a deal on Nov 18 ’24 to sell 12099.0 shares. Meanwhile, Chief Legal & Compliance Offic Quirk Gerald E sold 46657.0 shares on Nov 19 ’24.
